Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.

Item

http://www.wikidata.org/entity/Q39245161

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Optimal planning target volume ...... risk prostate cancer patients.

@en

Optimal planning target volume ...... risk prostate cancer patients.

@nl

type

Item

label

Optimal planning target volume ...... risk prostate cancer patients.

@en

Optimal planning target volume ...... risk prostate cancer patients.

@nl

prefLabel

Optimal planning target volume ...... risk prostate cancer patients.

@en

Optimal planning target volume ...... risk prostate cancer patients.

@nl

P1476

Optimal planning target volume ...... risk prostate cancer patients.

@en

P2093

Benjamin K Hinton

http://www.w3.org/2001/XMLSchema#string

John B Fiveash

http://www.w3.org/2001/XMLSchema#string

Michael C Dobelbower

http://www.w3.org/2001/XMLSchema#string

Robert Y Kim

http://www.w3.org/2001/XMLSchema#string

Rojymon Jacob

http://www.w3.org/2001/XMLSchema#string

Xingen Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of patient positioning errors based on in-line cone beam CTs: clinical implementation and first experiences

RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

The clinical application of intensity-modulated radiation therapy.

An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.

Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.

P304

941269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/941269

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236085352

http://www.w3.org/2001/XMLSchema#string

P698

23533814

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3606762

http://www.w3.org/2001/XMLSchema#string